Category: Abbott Laboratories
Here's a look at some of the top legal news stories for medical device companies this week: Could Medtronic-Covidien deal get caught in anti-inversion legislation?; Medtronic fights tax dodging rhetoric in Covidien merger; Travelers holds out on BD's $67M coverage claim; Abbott CEO defends inversions amid corporate exodus furor; Steris, Medtrica win legal fees in Cygnus Medical patent spat;
Abbott Labs reports a strong 2nd quarter driven in large part by diagnostics, but the medical device segment took a hit in U.S. sales, leading to a pretty flat quarter.
Illinois-based Abbott (NYSE:ABT) released a 2nd-quarter earnings report showing some strong momentum, but the healthcare giant's medical device sector didn't fare so well.
Abbott chairman & CEO Miles White chides critics of corporate inversions as Capitol Hill mulls legislation to strip tax benefits for companies that shift their headquarters overseas.
Here's a look at some of the top Wall Street stories for medical device companies this week: Ocular Therapeutix sets terms for IPO; Allergan renews fight against hostile Valeant takeover; Abbott to deal pharma line to Mylan for $5.3B; Exo-suit maker ReWalk files for $57.5M IPO; Intersect ENT sets terms for $65M IPO
Abbott's medical device business posts meager growth for the 2nd quarter, despite overall sales and earnings coming in ahead of expectations.
Here's a look at some of the top regulatory stories for medical device companies this week: Shareholder files class action lawsuit to block Covidien-Medtronic merger; St. Jude drops $200M on NeuroTherm for spinal pain device; Allergan renews fight against hostile Valeant takeover; Abbott to deal pharma line to Mylan for $5.3B
Abbott agrees to deal its specialty and branded generic pharmaceutical line to Mylan for $5.3 billion.